SIONNA THERAPEUTICS, INC. Research and Development Expense
SIONNA THERAPEUTICS, INC. (SION) reported Research and Development Expense of $21.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $21.86M, a 42.13% increase year-over-year.
- SIONNA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $18.96M, a 38.74% increase year-over-year.
- SIONNA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $15.17M, a 6.42% increase year-over-year.
- SIONNA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $16.04M, a 34.73% decline year-over-year.
- SIONNA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $60.26M, a 5.19% increase from fiscal 2024.
- SIONNA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $57.29M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.86M 10-Q · filed 2026-08-06 | $40.83M 10-Q · filed 2026-08-06 | $55.99M derived: sum of 3 quarters · filed 2026-08-06 | $72.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.96M 10-Q · filed 2026-05-12 | $34.13M derived: sum of 2 quarters · filed 2026-05-12 | $50.17M derived: sum of 3 quarters · filed 2026-05-12 | $65.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $15.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $31.21M derived: sum of 2 quarters · filed 2026-03-02 | $46.59M derived: sum of 3 quarters · filed 2026-08-06 | $60.26M 10-K · filed 2026-03-02 |
| 2025-09-30 | $16.04M 10-Q · filed 2025-11-05 | $31.43M derived: sum of 2 quarters · filed 2026-08-06 | $45.09M 10-Q · filed 2025-11-05 | $59.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $15.38M 10-Q · filed 2026-08-06 | $29.05M 10-Q · filed 2026-08-06 | $43.30M derived: sum of 3 quarters · filed 2026-08-06 | $67.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $13.67M 10-Q · filed 2026-05-12 | $27.92M derived: sum of 2 quarters · filed 2026-05-12 | $52.50M derived: sum of 3 quarters · filed 2026-05-12 | $60.74M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $14.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $38.84M derived: sum of 2 quarters · filed 2026-03-02 | $47.07M derived: sum of 3 quarters · filed 2026-03-02 | $57.29M 10-K · filed 2026-03-02 |
| 2024-09-30 | $24.58M 10-Q · filed 2025-11-05 | $32.81M derived: sum of 2 quarters · filed 2025-11-05 | $43.03M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $8.23M 10-Q · filed 2025-08-11 | $18.45M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $10.22M 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |